( MENAFN - Baystreet) Issued on behalf of Oncolytics Biotech Inc.

The market is taking notice. Analysts predict the global immunotherapy market will soar to $258 billion by 2031, powered by breakthroughs like checkpoint inhibitors and next-gen therapies.

Patients, clinicians and researchers have much to thank John A. Thompson, MD, for when he retires at the end of 2024 after 40 ...

Immune checkpoint inhibitors (ICIs) have shown significant promise in treating tumors. Immune checkpoint inhibitors are a form of immunotherapy, which redi | Immunology ...

Cancer immunotherapy has revolutionized the treatment landscape for various malignancies, offering new hope for patients. However, recent evidence has highlighted significant sex disparities in the ...

Immunotherapies have become a cornerstone in cancer treatment, with current therapies like checkpoint inhibitors enhancing ...

New treatments and adverse events impacting patient quality of life were among the topics of interest in 2024.

Another checkpoint inhibitor has entered the fray, as Checkpoint Therapeutics has passed the FDA’s checkpoint with its PD-L1 inhibitor cosibelimab. The FDA has approved cosibelimab under the brand ...

A deep learning radiomic biomarker has been developed and validated to predict responses to immune checkpoint inhibitors in ...

The results, reported at the San Antonio Breast Cancer Symposium (SABCS), added to the history of mixed messages from trials ...

Patients with heavily pretreated microsatellite stable metastatic colorectal cancer (CRC) had survival benefits after using ...